Jose Cervera

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1557948/publications.pdf Version: 2024-02-01



LOSE CEDVEDA

#	Article	IF	CITATIONS
1	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
2	Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea. Leukemia, 2021, 35, 623-627.	3.3	12
3	Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 659-668.	0.6	10
4	Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain. European Journal of Haematology, 2021, 106, 724-733.	1.1	1
5	A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms. Cancers, 2021, 13, 1947.	1.7	5
6	Aberrant Alternative Splicing in U2af1/Tet2 Double Mutant Mice Contributes to Major Hematological Phenotypes. International Journal of Molecular Sciences, 2021, 22, 6963.	1.8	5
7	Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). Leukemia Research, 2021, 109, 106612.	0.4	11
8	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature Communications, 2021, 12, 6233.	5.8	17
9	Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia. British Journal of Haematology, 2020, 188, 605-622.	1.2	25
10	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	15.2	372
11	Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia. Journal of Personalized Medicine, 2020, 10, 244.	1.1	1
12	Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene. Cancers, 2020, 12, 624.	1.7	77
13	Factor XIII deficiency in two Spanish families with a novel variant in gene F13A1 detected by next-generation sequencing; symptoms and clinical management. Journal of Thrombosis and Thrombolysis, 2020, 50, 686-688.	1.0	4
14	Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7. Leukemia, 2020, 34, 2441-2450.	3.3	14
15	Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype. Scientific Reports, 2020, 10, 5904.	1.6	8
16	Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation. Annals of Hematology, 2019, 98, 2151-2162.	0.8	2
17	Clinical and molecular characterization by next generation sequencing of Spanish patients affected by congenital deficiencies of fibrinogen. Thrombosis Research, 2019, 180, 115-117.	0.8	8
18	Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis. Annals of Hematology, 2019, 98, 2081-2088.	0.8	16

#	Article	IF	CITATIONS
19	RNA Sequencing Analysis for the Identification of a PCM1/PDGFRB Fusion Gene Responsive to Imatinib. Acta Haematologica, 2019, 142, 92-97.	0.7	6
20	CRISPR to fix bad blood: a new tool in basic and clinical hematology. Haematologica, 2019, 104, 881-893.	1.7	26
21	Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics. Journal of Molecular Diagnostics, 2019, 21, 228-240.	1.2	24
22	Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. Leukemia and Lymphoma, 2019, 60, 1146-1155.	0.6	12
23	TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes. Blood, 2019, 134, 675-675.	0.6	17
24	Germinal Predisposition in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction: Identification of Deleterious Variants in Microsatellite Instability Genes. Blood, 2019, 134, 4226-4226.	0.6	0
25	Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes. Haematologica, 2018, 103, e400-e403.	1.7	9
26	GuÃa práctica de tratamiento urgente de la microangiopatÃa trombótica. Medicina ClÃnica, 2018, 151, 123.e1-123.e9.	0.3	7
27	Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance. Genes Chromosomes and Cancer, 2018, 57, 547-556.	1.5	3
28	The modular network structure of the mutational landscape of Acute Myeloid Leukemia. PLoS ONE, 2018, 13, e0202926.	1.1	5
29	Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Leukemia and Lymphoma, 2017, 58, 145-152.	0.6	7
30	Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment. Leukemia and Lymphoma, 2017, 58, 2880-2894.	0.6	12
31	Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group. Leukemia Research, 2017, 63, 85-89.	0.4	9
32	Negative impact on clinical outcome of the mutational co-occurrence of <i>SF3B1</i> and <i>DNMT3A</i> in refractory anemia with ring sideroblasts (RARS). Leukemia and Lymphoma, 2017, 58, 1686-1693.	0.6	14
33	Impact of <i>ABC</i> single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. Leukemia and Lymphoma, 2017, 58, 1197-1206.	0.6	33
34	Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts. Blood Cancer Journal, 2017, 7, 630.	2.8	11
35	Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes. Oncotarget, 2017, 8, 106948-106961.	0.8	38
36	Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with <i>TP53</i>	0.8	29

#	Article	IF	CITATIONS
37	Impact of <scp>SNP</scp> array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases. American Journal of Hematology, 2016, 91, 185-192.	2.0	18
38	Analysis of the Possible Persistent Genotoxic Damage in Workers Linked to the Ardystil Syndrome. Genetic Testing and Molecular Biomarkers, 2016, 20, 94-97.	0.3	1
39	Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood, 2016, 128, 1408-1417.	0.6	249
40	Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes. Genes Chromosomes and Cancer, 2016, 55, 322-327.	1.5	7
41	Study of the S427G polymorphism and ofMYBL2variants in patients with acute myeloid leukemia. Leukemia and Lymphoma, 2016, 57, 429-435.	0.6	10
42	The Mutational Landscape of Acute Promyelocytic Leukemia Reveals an Interacting Network of Co-Occurrences and Recurrent Mutations. PLoS ONE, 2016, 11, e0148346.	1.1	23
43	Comparison of the Molecular Spectrum of Lenalidomide-Treated Myelodysplastic Syndrome with and without Del(5q). Blood, 2016, 128, 3172-3172.	0.6	0
44	Clonal Hematopoiesis Landscape in Patients with De Novo Acute Myeloid Leukemia By Deep Sequencing. Blood, 2016, 128, 598-598.	0.6	0
45	Influence of Cytarabine Metabolic Pathway Polymorphisms in Acute Myeloid Leukemia Induction Treatment. Blood, 2016, 128, 5130-5130.	0.6	0
46	CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia. Haematologica, 2015, 100, e183-e185.	1.7	20
47	Correlation of myelodysplastic syndromes with i(17)(q10) and <i><scp>TP</scp>53</i> and <i><scp>SETBP</scp>1</i> mutations. British Journal of Haematology, 2015, 171, 137-141.	1.2	11
48	Somatic Genetic and Epigenetic Architecture of Myelodysplastic Syndromes Arising from GATA2 Deficiency. Blood, 2015, 126, 299-299.	0.6	10
49	Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia. Blood, 2015, 126, 4842-4842.	0.6	1
50	Influence of Single Nucleotide Polymorphisms in Anthracycline Metabolism Pathway in Standard Induction of Acute Myeloid Leukemia. Blood, 2015, 126, 4845-4845.	0.6	1
51	Validation of a Next-Generation Sequencing Panel for AML Routine Diagnosis. Blood, 2015, 126, 1403-1403.	0.6	0
52	Simplified in-House Deep Sequencing Method of Inmunoglobulin Genes for Minimal Residual Dissease Quantification and Risk Stratification in Multiple Myeloma. Blood, 2015, 126, 2972-2972.	0.6	0
53	Single-Nucleotide Polymorphism Array-Based Karyotyping of Acute Promyelocytic Leukemia. PLoS ONE, 2014, 9, e100245.	1.1	7
54	Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with riskâ€adapted protocols. Cancer, 2014, 120, 3958-3964.	2.0	24

#	Article	IF	CITATIONS
55	In vitro all-trans retinoic acid sensitivity of acute myeloid leukemia blasts with NUP98/RARG fusion gene. Annals of Hematology, 2014, 93, 1931-1933.	0.8	21
56	Sister chromatid exchange, (SCE), High-Frequency Cells (HFCs) and SCE distribution patterns in peripheral blood lymphocytes of Spanish adult smokers compared to non-smokers. Food and Chemical Toxicology, 2014, 66, 107-112.	1.8	9
57	Prognostic Impact of Anthracycline Metabolism Gene Polymorphisms in Newly Diagnosed Acute Myeloid Leukemia Adults. Blood, 2014, 124, 2237-2237.	0.6	1
58	Utility of SNP Arrays in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features or No Metaphases. Blood, 2014, 124, 4659-4659.	0.6	0
59	Somatic Mutations of ASXL1, RUNX1 and SETBP1 Improve Prognostic Stratification of Patients with Chronic Myelomonocytic Leukemia. Blood, 2014, 124, 1915-1915.	0.6	6
60	Genomic Microarray Alterations Add Prognostic Power to the IPSS-R in MDS with Normal Karyotype. Blood, 2014, 124, 3262-3262.	0.6	0
61	Prognostic Impact of Cytarabine Pathway Gene Polymorphisms in Acute Myeloid Leukemia Adults Undergoing Induction Chemotherapy. Blood, 2014, 124, 5223-5223.	0.6	0
62	Novel Real-Time Polymerase Chain Reaction Assay for Simultaneous Detection of Recurrent Fusion Genes in Acute Myeloid Leukemia. Journal of Molecular Diagnostics, 2013, 15, 678-686.	1.2	8
63	Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome. Leukemia Research, 2013, 37, 769-776.	0.4	11
64	Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: Review of 5,654 patients with an evaluable karyotype. Genes Chromosomes and Cancer, 2013, 52, 753-763.	1.5	15
65	Frequency of dicentrics and contamination levels in Ukrainian children and adolescents from areas near Chernobyl 20 years after the nuclear plant accident. International Journal of Radiation Biology, 2013, 89, 944-949.	1.0	2
66	Radioprotective activity and cytogenetic effect of resveratrol in human lymphocytes: An in vitro evaluation. Food and Chemical Toxicology, 2013, 51, 391-395.	1.8	32
67	Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: Does â°'7/7qâ^' detection by FISH have prognostic value?. Leukemia Research, 2013, 37, 416-421.	0.4	16
68	Adverse prognostic value of MYBL2 overexpression and association with microRNA-30 family in acute myeloid leukemia patients. Leukemia Research, 2013, 37, 1690-1696.	0.4	36
69	WT1 isoform expression pattern in acute myeloid leukemia. Leukemia Research, 2013, 37, 1744-1749.	0.4	11
70	Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. British Journal of Haematology, 2013, 162, 74-86.	1.2	73
71	Screening forIDHmutations in chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2013, 54, 406-407.	0.6	4
72	Assessing an Improved Protocol for Plasma microRNA Extraction. PLoS ONE, 2013, 8, e82753.	1.1	81

#	Article	IF	CITATIONS
73	<i>BRAF</i> V600E mutation in adult acute lymphoblastic leukemia. Leukemia and Lymphoma, 2013, 54, 1105-1106.	0.6	4
74	Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing. Genes Chromosomes and Cancer, 2013, 52, 1167-1177.	1.5	44
75	Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood, 2013, 121, 3005-3015.	0.6	251
76	Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes. British Journal of Haematology, 2012, 159, 311-321.	1.2	25
77	Rapid Screening of ASXL1, IDH1, IDH2, and c-CBL Mutations in de Novo Acute Myeloid Leukemia by High-Resolution Melting. Journal of Molecular Diagnostics, 2012, 14, 594-601.	1.2	12
78	New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. Journal of Clinical Oncology, 2012, 30, 820-829.	0.8	584
79	In vitro cytogenetic and genotoxic effects of curcumin on human peripheral blood lymphocytes. Food and Chemical Toxicology, 2012, 50, 3229-3233.	1.8	19
80	Analysis of SNP rs16754 of WT1 gene in a series of de novo acute myeloid leukemia patients. Annals of Hematology, 2012, 91, 1845-1853.	0.8	8
81	Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia. Leukemia Research, 2012, 36, 174-181.	0.4	17
82	Absence of mutations in the activation loop and juxtamembrane domains of VEGFR-1 and VEGFR-2 gene in chronic myelomonocytic leukemia (CMML). Leukemia Research, 2012, 36, e50-e51.	0.4	0
83	Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. Cancer, 2012, 118, 127-133.	2.0	43
84	Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia. Annals of Hematology, 2012, 91, 1-7.	0.8	13
85	Prognostic value of cytogenetics in adult patients with Philadelphia-negative acute lymphoblastic leukemia. Annals of Hematology, 2012, 91, 19-25.	0.8	5
86	Association of MDM2 Gene Polymorphisms SNP285 and 309 with Myelodysplastic Syndromes (MDS) Susceptibility and Outcome Blood, 2012, 120, 2823-2823.	0.6	0
87	Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica, 2011, 96, 375-383.	1.7	226
88	A novel NUP98/RARG gene fusion in acute myeloid leukemia resembling acute promyelocytic leukemia. Blood, 2011, 117, 242-245.	0.6	65
89	Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia. Haematologica, 2011, 96, 1448-1456.	1.7	45
90	CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. Haematologica, 2011, 96, 1557-1559.	1.7	31

#	Article	IF	CITATIONS
91	Correlation Between Preoperative Magnetic Resonance Imaging and Surgical Margins with Modified Mohs for Dermatofibrosarcoma Protuberans. Dermatologic Surgery, 2011, 37, 1638-1645.	0.4	53
92	Assessment inÂvitro of radioprotective efficacy of curcumin and resveratrol. Radiation Measurements, 2011, 46, 962-966.	0.7	29
93	Aberrant methylation of tumor suppressor genes in patients with refractory anemia with ring sideroblasts. Leukemia Research, 2011, 35, 479-483.	0.4	9
94	Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome. Leukemia Research, 2011, 35, 834-836.	0.4	11
95	Gene Microdeletions in Adult and Pediatric Acute Lymphoblastic Leukemia,. Blood, 2011, 118, 3539-3539.	0.6	2
96	Quantitative Expression Analysis of WT1 Main Isoforms in AML. Blood, 2011, 118, 1469-1469.	0.6	0
97	Analysis of ASXL1, IDH1, IDH2, c-CBL, and WT1 Mutations in De Novo Acute Myeloid Leukaemia. Blood, 2011, 118, 1450-1450.	0.6	0
98	Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica, 2010, 95, 424-431.	1.7	84
99	Epigenetic regulation of the nonâ€canonical Wnt pathway in acute myeloid leukemia. Cancer Science, 2010, 101, 425-432.	1.7	43
100	New Chemistry Cartridge for the GEM Premier 4000 Critical Care Analyzer, Including Electrochemical Sensors for Creatinine, Urea, and Measured Bicarbonate. Point of Care, 2010, 9, 1-7.	0.5	1
101	A new reliable fluorescencein situhybridization method for identifying multiple specific cytogenetic abnormalities in acute myeloid leukemia. Leukemia and Lymphoma, 2010, 51, 680-685.	0.6	3
102	DNA Methylation Profiles and Their Relationship with Cytogenetic Status in Adult Acute Myeloid Leukemia. PLoS ONE, 2010, 5, e12197.	1.1	73
103	Loss of the Y Chromosome in MDS - Age-Related Phenomenon or Clonal Abnormality?. Blood, 2010, 116, 4008-4008.	0.6	Ο
104	Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies. Haematologica, 2009, 94, 827-832.	1.7	29
105	Rapid Detection of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia Using High-Resolution Melting Analysis. Journal of Molecular Diagnostics, 2009, 11, 458-463.	1.2	24
106	Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): Comparison with WT1 gene expression. Clinica Chimica Acta, 2008, 395, 120-123.	0.5	32
107	Measurement of Creatinine in Whole Blood Samples Supplemented to Achieve Increased Creatinine Concentrations. Clinical Chemistry, 2008, 54, 451-452.	1.5	6
108	Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q Haematologica, 2008, 93, 1001-1008.	1.7	36

#	Article	IF	CITATIONS
109	Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood, 2008, 112, 3383-3390.	0.6	74
110	Lack of RPS14 promoter aberrant methylation supports the haploinsufficiency model for the 5q- syndrome. Blood, 2008, 112, 918-918.	0.6	78
111	A comprehensive strategy for the subtyping of patients with Fanconi anaemia: conclusions from the Spanish Fanconi Anemia Research Network. Journal of Medical Genetics, 2007, 44, 241-249.	1.5	47
112	The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. Haematologica, 2007, 92, 308-314.	1.7	76
113	1: Analysis of Risk Factors in Adults Transplanted with UCB for Treatment of Hematologic Malignancy. Biology of Blood and Marrow Transplantation, 2007, 13, 1393.	2.0	0
114	The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia. Leukemia Research, 2007, 31, 947-953.	0.4	40
115	Could ATRA/Idarubicin treatment of acute promyelocytic leukemia induce the appearance of new clonal cytogenetic abnormalities in patients in complete remission?. Leukemia Research, 2007, 31, 1315-1317.	0.4	2
116	Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. British Journal of Haematology, 2007, 136, 590-596.	1.2	75
117	MLL amplification in acute myeloid leukemia. Cancer Genetics and Cytogenetics, 2007, 174, 127-131.	1.0	17
118	Incidence and Characteristics of Acute Promyelocytic Leukemia in Adult Patients. A Single Centre Registry Study Blood, 2007, 110, 4301-4301.	0.6	0
119	Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression. Leukemia Research, 2006, 30, 1471-1491.	0.4	94
120	A t(17;20)(q21;q12) masking a variant t(15;17)(q22;q21) in a patient with acute promyelocytic leukemia. Cancer Genetics and Cytogenetics, 2006, 168, 73-76.	1.0	9
121	High-level amplification of the RUNX1 gene in two cases of childhood acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 2006, 170, 171-174.	1.0	9
122	EVI1is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements. Genes Chromosomes and Cancer, 2006, 45, 349-356.	1.5	51
123	Long-Term Outcome and Prognostic Factors after Single-Unit Umbilical Cord-Blood Transplantation (UCBT) for Adults with Hematologic Malignancies Blood, 2006, 108, 3129-3129.	0.6	0
124	The JAK2 V617F Mutation Identifies Specific Subgroups of Myelodysplastic Syndrome (MDS) Blood, 2006, 108, 2610-2610.	0.6	0
125	SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor. British Journal of Haematology, 2005, 129, 791-794.	1.2	22
126	Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica, 2005, 90, 1168-78.	1.7	163

#	Article	IF	CITATIONS
127	Immunofluorescent analysis with the anti-PML monoclonal antibody PC-M3 for rapid and accurate genetic diagnosis of acute promyelocytic leukemia. Annals of Hematology, 2004, 83, 687-690.	0.8	21
128	Locked Nucleic Acid-Enhanced Detection of 1100delC*CHEK2 Germ-Line Mutation in Spanish Patients with Hematologic Malignancies. Clinical Chemistry, 2004, 50, 2201-2204.	1.5	7
129	Additional Chromosome Abnormalities Have No Prognostic Value in Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Anthracycline-Based Chemotherapy: An Update of the APL96 and APL99 Pethema Protocols Blood, 2004, 104, 2019-2019.	0.6	5
130	Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica, 2004, 89, 926-33.	1.7	97
131	Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica, 2003, 88, 19-24.	1.7	135
132	The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Human Molecular Genetics, 2002, 11, 1391-1397.	1.4	139
133	Identification of two atypical PML–RARα transcripts in two patients with acute promyelocytic leukemia. Leukemia Research, 2002, 26, 439-442.	0.4	18
134	FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies. Leukemia Research, 2002, 26, 725-730.	0.4	41
135	Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. Blood, 2001, 98, 2332-2338.	0.6	220
136	Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia. Leukemia Research, 2001, 25, 685-692.	0.4	12
137	Graft-versus-tumour effect in non-small-cell lung cancer after allogeneic peripheral blood stem cell transplantation. SHORT REPORT. British Journal of Haematology, 2000, 111, 708-710.	1.2	29
138	Liver disease as primary manifestation of multiple myeloma in a young man. Leukemia Research, 1999, 23, 403-405.	0.4	14